Monday 16 November 2026
Export KYNB’s income statement to Excel — free account
Kyntra Bio Inc
KYNBKyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.
- Revenue
- n/m
- EPS
- n/m
- Free cash flow
- n/m
Quarter to June 2026, against a year earlier
3.44
0.15
−4.18%
Follow KYNB
Alert me
Ratios over time Q3 FY25 to Q2 FY26
Returns on capital
ROIC was 0.0% in Q2 FY26, the highest of these four quarters.
| Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|
| ROE | −189.9% | −165.2% | −144.0% | −157.8% |
| ROIC | 0.0% | 0.0% | 0.0% | 0.0% |
Debt
Net debt is 5.17× a year’s EBITDA. Debt is 0.00× equity.
| Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|
| Debt / equity | 0.0× | 0.0× | 0.0× | 0.0× |
| Net debt / EBITDA | 22.6× | 6.6× | 6.2× | 5.2× |
Cash cycle, in days
Customers pay in 27 days, inventory is held 285 days and suppliers are paid in 633. Suppliers fund 321 days of working capital.
| Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|
| Cash cycle | 86 | 11 | 106 | −321 |
| Days to pay suppliers | −334 | 2458 | 422 | 633 |
| Days to be paid | 5 | 12 | 247 | 27 |
Per share, from Q3 FY25
Since Q3 FY25, per share: revenue has fallen 44.4%.
| Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|
| Revenue | 1.0× | 0.8× | 0.9× | 0.6× |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (157.83%) | (144.04%) | (165.18%) | (189.86%) |
+8 more TTM periods Free account |
|
Piotroski F-Score |
5 | 5 | 5 | 5 | |
| 131.26% | 119.06% | 109.81% | 107.44% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
301.38% | 223.39% | 262.71% | 221.30% | |
Average Days of Receivables |
27.43 | 247.29 | 12.24 | 5.32 | |
Free Cash Flow per Share |
(9.40) | (5.28) | (1.19) | (4.18) | |
Free Cash Flow |
(38.05) | (21.38) | (4.81) | (16.88) | |
Capital Expenditures |
— | — | (0.04) | 0.03 | |
| Other line items | |||||
Cash ROIC |
(61.68%) | (37.86%) | (6.69%) | (14.81%) | |
Accounts Receivable Turnover |
19.12 | 2.87 | 18.48 | 0.57 | |
Accounts Payable Turnover |
0.48 | 0.71 | 0.13 | (0.78) | |
Inventory Turnover |
1.19 | 1.35 | 0.16 | (0.40) | |
Average Days of Payables |
633.50 | 421.61 | 2,458.50 | (333.86) | |
Days of Inventory on Hand |
285.45 | 280.08 | 2,457.19 | (253.30) | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
495.21% | 294.50% | 365.17% | 278.56% | |
Selling, General and Administrative Expense of Revenue |
599.39% | 342.32% | 430.26% | 347.10% | |
Share Based Compensation of Revenue |
86.33% | 65.53% | 102.11% | 67.06% | |
Interest Coverage |
(5.42) | (5.02) | (5.24) | (4.61) | |
Operating CF/Net income |
(0.21) | (0.13) | (0.03) | (0.08) | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | (0.06) | 0.02 | |
Revenue per Share |
1.14 | 1.84 | 1.59 | 2.05 | |
Operating CF per Share |
(9.40) | (5.28) | (1.18) | (4.18) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.01 | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.00 |
Columns are period end dates · fundamentals updated 25 Oct 2026